Frank Pajonk

Frank Pajonk is a Professor in the Department of Radiation Oncology and Neurosurgery at the David Geffen School of Medicine, University of California, Los Angeles (UCLA). His research focuses on cancer stem cells, radiation biology, and therapeutic strategies targeting glioblastoma and breast cancer. He holds dual appointments in Radiation Oncology and Neurosurgery, reflecting his interdisciplinary approach to oncology. Pajonk completed his MD and PhD at Albert-Ludwigs University, followed by habilitation (Venia Legendi) in Germany.

Education and Training:

• MD, Albert-Ludwigs University
• PhD, Albert-Ludwigs University
• Habilitation (Venia Legendi), Albert-Ludwigs University

Research interests include radiation-induced cellular plasticity, cancer stem cell biology, and the development of novel therapies targeting glioblastoma. His work explores how radiation therapy can be combined with drugs like quetiapine or dopamine antagonists to enhance treatment efficacy. Key themes include the mevalonate pathway's role in cancer recurrence and the use of artificial intelligence in scientific research ethics.

Recent publications highlight studies on mesothelioma stem cells, glioblastoma recurrence mechanisms, and the impact of radiation on neural stem cells. Pajonk leads NIH-funded projects, such as R01CA281682 (Utilizing Radiation-Induced Multi-potency) and R01CA260886 (CTEP Portfolio Compounds in GBM). His lab (Pajonk Lab) collaborates on preclinical models and drug development.

Grants and Funding:

• NIH R01CA281682 (2023–2028)
• CIRM DISC2-14083 (2023–2026)
• NIH R01CA260886 (2022–2027)

Pajonk's work emphasizes translational research, bridging basic science and clinical applications in radiation oncology and neuro-oncology.